Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: It is a violation to ask Agora to review a violation!

Obviously, if the BoD is going to increase the share price, the mere collecting and distribution of MMP Portfolio revenues doesn't really qualify.

This only leaves Holocom and PDSG.

Does it stand to reason that if either one or both show profitability, this will be reflected in the share price, and as such, any complaints about the BoD not generating shareholder value fail miserably and are thus moot?

It is appreciated that fingers might be pointed to certain write-downs, and in that event would simply request examples of companies with a 100% success rate for M&As.

.

.

.

Be well

Share
New Message
Please login to post a reply